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Abstract
Aim: Excess mitochondrial reactive oxygen species (mROS) play a vital role in
cardiac ischemia reperfusion (IR) injury. P66Shc, a splice variant of the ShcA
adaptor protein family, enhances mROS production by oxidizing reduced
cytochrome c to yield H2O2. Ablation of p66
Shc protects against IR injury, but it is
unknown if and when p66Shc is activated during cardiac ischemia and/or
reperfusion and if attenuating complex I electron transfer or deactivating PKCb
alters p66Shc activation during IR is associated with cardioprotection.
Methods: Isolated guinea pig hearts were perfused and subjected to increasing
periods of ischemia and reperfusion with or without amobarbital, a complex I
blocker, or hispidin, a PKCb inhibitor. Phosphorylation of p66Shc at serine 36 and
levels of p66Shc in mitochondria and cytosol were measured. Cardiac functional
variables and redox states were monitored online before, during and after ischemia.
Infarct size was assessed in some hearts after 120 min reperfusion.
Results: Phosphorylation of p66Shc and its translocation into mitochondria
increased during reperfusion after 20 and 30 min ischemia, but not during ischemia
only, or during 5 or 10 min ischemia followed by 20 min reperfusion.
Correspondingly, cytosolic p66Shc levels decreased during these ischemia and
reperfusion periods. Amobarbital or hispidin reduced phosphorylation of p66Shc and
its mitochondrial translocation induced by 30 min ischemia and 20 min reperfusion.
Decreased phosphorylation of p66Shc by amobarbital or hispidin led to better
functional recovery and less infarction during reperfusion.
OPEN ACCESS
Citation: Yang M, Stowe DF, Udoh KB, Heisner
JS, Camara AKS (2014) Reversible Blockade of
Complex I or Inhibition of PKCb Reduces
Activation and Mitochondria Translocation of
p66Shc to Preserve Cardiac Function after
Ischemia. PLoS ONE 9(12): e113534. doi:10.1371/
journal.pone.0113534
Editor: Guo-Chang Fan, University of Cincinnati,
College of Medicine, United States of America
Received: August 1, 2014
Accepted: October 26, 2014
Published: December 1, 2014
This is an open-access article, free of all copyright,
and may be freely reproduced, distributed,
transmitted, modified, built upon, or otherwise used
by anyone for any lawful purpose. The work is
made available under the Creative Commons CC0
public domain dedication.
Data Availability: The authors confirm that all data
underlying the findings are fully available without
restriction. All relevant data are within the paper.
Funding: This work was supported by funding
from the National Heart Lung and Blood Institute of
the National Institutes of Health R01 HL 095122
NIH (awarded to Dr. Camara) and R01 HL 089514
NIH (awarded to Dr. Stowe). The funders had no
role in study design, data collection and analysis,
decision to publish, or preparation of the manu-
script.
Competing Interests: The authors have declared
that no competing interests exist.
PLOS ONE | DOI:10.1371/journal.pone.0113534 December 1, 2014 1 / 20
Conclusion: Our results show that IR activates p66Shc and that reversible
blockade of electron transfer from complex I, or inhibition of PKCb activation,
decreases p66Shc activation and translocation and reduces IR damage. These
observations support a novel potential therapeutic intervention against cardiac IR
injury.
Introduction
Mitochondria are proximal effectors and determinants of cell fate during ischemia
and reperfusion (IR)-mediated oxidative stress. Thus they are also potential
therapeutic targets to ameliorate oxidative damage [1]. Excess mitochondrial
reactive oxygen species (mROS) emission plays a key role in contributing to
cardiac IR injury [2]. It is generally accepted that in mitochondria the superoxide
anion (O2
2N), the precursor of most ROS, is generated within the electron
transport chain (ETC) complexes (e.g. I, II and III), wherein the leak of a single
electron reduces O2 to O2
2N [3–5].
Recent reports indicate that p66Shc, a splice variant of the ShcA adaptor protein
family, also contributes to mROS production [1, 6]. Giorgio et al. [6] suggested
that p66Shc utilizes reducing equivalents of the ETC by oxidizing reduced
cytochrome c (cyt c) to catalyze the reduction of O2 to H2O2. Electron transfer
from cyt c to p66Shc would designate it as a mitochondrial redox enzyme [6] that
could play an alternative role as a signaling molecule for mitochondrial-mediated
cell apoptosis [7, 8]. Indeed, p66Shc gene ablation (p66Shc2/2) has been shown to
reduce hypoxia/reoxygenation-induced damage to hepatocytes [9] and to decrease
necrosis and apoptosis of myofibrils after hind limb ischemia compared to the
wild type [10]. Furthermore, in isolated perfused hearts, p66Shc2/2 mice
compared to wild type mice exhibited both reduced IR-mediated LDH release
into the coronary effluent and abrogated lipoperoxidation [11].
The pathway leading to p66Shc activation and translocation into mitochondria
is unclear. Excess H2O2 or ultraviolet light (UV) irradiation has been shown to
activate a serine-threonine protein kinase C b (PKCb), which led to p66Shc
phosphorylation at serine 36, and to trigger mitochondrial accumulation of the
protein after its recognition by the prolyl isomerase Pin1 in mouse embryonic
fibroblasts (MEF) [12, 13]. Pinton et al. [13] reported that in MEF, inhibition of
PKCb with hispidin inhibited H2O2 -induced p66
Shc phosphorylation; over-
expression of PKCb mediated H2O2-induced mitochondrial dysfunction in wild
type MEFs, but not in p66Shc2/2 MEFs. It was reported that activation of PKCbII
in ventricular tissue increased after IR and that gene deletion or pharmacological
blockade of PKCbII was associated with protection against ischemia [14].
Mitochondrial ETC complexes are involved in mROS production during IR.
Moreover, O2
2N generated at mitochondrial complex III can be attenuated by
limiting electron transfer from complex I, thereby provide protection against IR
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injury. We [15], and others [16], have reported that the therapeutic targeting of
complex I with amobarbital provided cardioprotection, in part, by decreasing
mROS production during IR. Amobarbital, a short-acting barbiturate, reversibly
attenuates complex I electron transfer at the rotenone site [17], decreased IR-
induced O2
2N generation and mitochondrial [Ca2+] overload [15], retarded
mitochondrial permeability transition pore (mPTP) opening [16], and improved
oxidative phosphorylation (OxPhos) [16]. These mitochondrial effects culmi-
nated in appreciable protection of cardiac function on reperfusion after ischemia
[15, 16]. However, targeting distal complexes of the ETC, especially complex IV, is
not protective against ischemic stress and may exacerbate injury. For example,
blocking complex IV before ischemia increased levels of reduced cyt c, a likely
substrate for p66Shc-mediated H2O2 generation [6] leading to more oxidative
stress.
Our aims were to explore if p66Shc is involved in IR induced mROS generation
and how ROS and p66Shc dynamically modulate each other during different
periods of cardiac ischemia and reperfusion. To address these objectives, we used
the perfused ex vivo guinea pig heart model and monitored: a) if and when p66Shc
is activated during cardiac ischemia and/or reperfusion; b) if activation of PKCbII
during IR induces p66Shc activation and mitochondrial translocation to contribute
to cardiac IR injury; c) if reversible attenuation of complex I electron transfer with
amobarbital during IR is associated with p66Shc activation.
Methods
Ethics Statements
Our animal protocols conformed to the Guide for the Care and Use of Laboratory
Animals (National Institutes of Health No. 85-23, Revised 1996). The Medical
College of Wisconsin IACUC, with the number AUA 1647, approved all our
animal studies.
Isolated heart preparation and measurements
Hearts were removed and prepared for study as described previously [18–22]. In
brief, guinea pigs were given heparin (1000 units) and ketamine (50 mg/kg) i.p.
before sacrifice. Hearts were harvested and perfused retrograde at constant
pressure (55 mmHg) via the aortic root with an oxygenated Krebs-Ringer’s (KR)
solution of the following composition (in mM): 138 Na+, 4.5 K+, 1.2 Mg2+, 2.5
Ca2+, 134 Cl2, 15 HCO3
2, 1.2 H2PO4
2, 11.5 glucose, 2 pyruvate, 16 mannitol, 0.1
probenecid, 0.05 EDTA, and 5 U/L insulin and gassed with 3% CO2, 97% O2
(pH 7.4) at 37 C˚. Systolic and diastolic left ventricular pressures (LVP), coronary
flow (CF) and heart rate were measured online continuously for all of perfused
hearts as described previously [18–22]. The aortic inflow line was clamped to
induce global ischemia. If ventricular fibrillation (VF) occurred on reperfusion,
250 mg of lidocaine was given via the aortic cannula to restore sinus rhythm.
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Protocols
At the end of the indicated times of ischemia and/or reperfusion, some hearts
were removed and immediately snap frozen in liquid N2 and stored at 280 C˚ for
later measurement of p66Shc and PKCbII phosphorylation (n53 hearts per
group). Other hearts were removed and mitochondria were immediately isolated
for assessment of cytosolic and mitochondrial changes in p66Shc levels (n53
hearts per group). Other hearts were removed at 120 min reperfusion to measure
infarct size (n58 hearts per group). In the complex I blocker treated groups,
hearts were perfused with 2.5 mM amobarbital (Amo) for 1 min before initiating
global ischemia [15]; in the PKCb antagonist treated groups, hearts were perfused
with 40 mM hispidin (His) for 10 min before ischemia. Amobarbital and hispidin
were administered up to the initiation of ischemia to ensure the presence of the
drugs in the heart during the entire period of ischemia and briefly during the
onset of reperfusion.
Infarct size measurement
After 120 min reperfusion, hearts were removed and the atria discarded. The
ventricles were cut into 3 mm sections, and then stained with 1% 2,3,5-
triphenyltetrazolium chloride (TTC) to measure infarct size. In living tissue, TTC
is reduced by pyridine nucleotide-linked dehydrogenase into a red, lipid-soluble
formazan that stains living tissue red. Infarcted tissue lacking this dehydrogenase
remains unstained. Infarct size of the TTC stained white area was determined as a
percentage of total ventricular heart weight [22, 23].
Measurement of NADH in isolated hearts
Tissue autofluorescence (arbitrary fluorescence units, afu) is an indicator of
NADH at lem 460 nm (lex 350 nm); it is primarily utilized to assess the
mitochondrial redox state (n56 isolated hearts/group) [15, 24, 25]. Motion
artifact was reduced by using lem 405 nm as a reference that is less sensitive to
changes in NADH [26]. Therefore, the ratio of auf at lem 460/lem 405 nm
indicates mitochondrial NADH.
Detection of O2
2N in isolated hearts loaded with dihydroethidium
(DHE)
The intracellular fluorescent probe DHE (Molecular Probes) was used to assess
O2
2N emission continuously during IR (n56 isolated hearts per group) as
described previously [15, 20, 24, 27]. After stabilization, hearts were loaded with
10 mM DHE dissolved in KR solution for 20 min; this was followed by washout of
residual, unincorporated DHE with KR solution for 20 min [15, 20]. The
fluorescence emitted (afu) after washout was adjusted to 0 afu (baseline) to
normalize the fluorescence intensity for all experiments. Changes in the DHE
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fluorescence signal, which represents O2
2N generation, were compared to the
baseline fluorescence signal values [15, 18, 27].
Preparation of cytosolic and mitochondrial fractions
Mitochondrial and cytosolic fractions were prepared using procedures described
previously [27–32] with minor modifications. All procedures were carried out at
4 C˚. Hearts were minced in a chilled isolation buffer containing (in mM) 200
mannitol, 50 sucrose, 5 KH2PO4, 5 MOPS, 1 EGTA and 0.1% fatty acid free BSA
at pH 7.15, then homogenized. The homogenized slurries were centrifuged at
8000 g for 10 min. The supernatant were collected and further centrifuged at
50,000 g for 30 min, and then the resulting supernatant was used as the cytosolic
fraction. The pellet from the 8,000 g centrifugation was resuspended in isolation
buffer containing protease inhibitors and spun at 750 g for 10 min; the
supernatant was collected and again centrifuged at 8000 g. The final mitochon-
drial pellet following this centrifugation was resuspended in isolation buffer and
then purified as described by Graham [33]. Mitochondria were layered on 30%
Percoll in isolation buffer, and then centrifuged for 30 min at 95,000 g. After
centrifugation, the lower part of the dense brown band containing the purified
mitochondria was collected and washed two times with isolation buffer. After
purification, the mitochondria were resuspended in isolation buffer containing
protease inhibitors and stored at 280 C˚ for later use. Mitochondrial and cytosolic
protein concentrations were assessed using Bio-Rad protein assay with bovine
serum albumin (BSA) as the standard.
Immunoprecipitation of mitochondrial proteins
Immunoprecipitation (IP) was performed as described previously [27, 34, 35] with
minor changes. Frozen hearts were pulverized under liquid nitrogen and then the
powder was lysed in RIPA buffer containing 50 mM Tris-Cl pH 7.4, 150 mM
NaCl, 1% deoxycholate, 1% Triton X-100, 0.1% SDS and protease inhibitors on
ice for 30 min. The sample was pre-cleared with 30 ml protein G Sepharose-4B
beads (Invitrogen) for 1 h at 4 C˚ with constant end-over-end shaking and then
centrifuged at 3000 g for 5 min. Supernatant was collected, adjusted to 2 mg/ml
protein concentration with RIPA buffer containing protease inhibitors, and
subjected to IP with an anti-Shc antibody (rabbit polyclonal IgG, Millipore) at 4 C˚
with constant end-over-end shaking overnight. The next day 30 ml of protein G
Sepharose-4B beads was added and the mixture was incubated for another 2 h
under the same conditions as above. The beads were collected and washed (five
times) with RIPA buffer. After washing and aspirating the washing buffer
completely, 50 ml Laemmli sample buffer containing 50 mM Tris-Cl, 10%
glycerol, 500 mM b-mercaptoethanol, 2% SDS, 0.01% w/v bromophenol blue and
protease inhibitors at pH 7.4, was added to the beads and boiled at 95 C˚ for
5 min. The immunoprecipated proteins were separated using SDS-PAGE and
then subjected to Western blot analyses.
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Western blot analyses
Mitochondrial protein (50 mg) or immunoprecipitates were resolved by SDS-
PAGE and transferred onto a PVDF membrane. Membranes were incubated with
specific primary antibodies: anti-Shc/p66 (pSer36) (mouse monoclonal, 1:1000,
Calbiochem); anti-Shc (total pool of p66Shc, mouse monoclonal, 1:1000, BD
Transduction Laboratories); PKCbII (rabbit polyclonal, 1:500 Santa Cruz); and P-
PKCbII/d (Ser660) (rabbit polyclonal, 1:500, Santa Cruz). Washed membranes
were incubated with the appropriate secondary antibody conjugated to HRP, then
immersed in an enhanced chemiluminescence detection solution (GE Healthcare)
and exposed to X-Ray film for autoradiography. To monitor the amounts of
loaded proteins and purity of isolated mitochondrial and cytosolic fractions,
specific antibody-blotted membranes were stripped and then probed with
antibodies against VDAC (rabbit polyclonal, 1:1000, Cell Signaling) or b-actin
(rabbit polyclonal, 1:500, Santa Cruz).
Statistical analysis
All results were expressed as means ¡SEM and were analyzed by one-way
ANOVA followed by a post-hoc analysis (Student-Newman-Keuls’ test) to
determine significant differences of means among groups. Isolated heart data were
collected for statistical evaluation at time points 30, 45, 50, and 65 min. P,0.05
was considered significantly different (two-tailed).
Results
Activation of p66Shc occurred during reperfusion after ischemia
We first examined if and when p66Shc was activated during cardiac IR by
determining the level of phosphorylation of p66Shc at serine 36 (Ser36), an
indication of p66Shc activation [12, 13]. After normalizing to total immunopre-
cipated p66Shc (Fig. 1A, bottom panel), phosphorylation of p66Shc at Ser36
increased on reperfusion in the IR groups compared to the time control (TC) and
ischemia only groups (Fig. 1A, upper panel); the increase in phosphorylation of
p66Shc at Ser36 occurred as early as 10 min reperfusion after 30 min ischemia and
was detectable for up to 60 min reperfusion. In the 20 and 30 min ischemia only
groups, the phosphorylation of p66Shc at Ser36 did not change compared to the
TC group. These results indicated that IR induced p66Shc activation and,
moreover, that p66Shc was activated only during reperfusion after ischemia and
not by ischemia alone.
P66Shc localized to mitochondria during reperfusion after ischemia
It was reported that after phosphorylation at Ser36, p66Shc is recognized by prolyl
isomerase Pin1, which enables the phosphorylated p66Shc to be translocated to the
IMM [13]. We therefore examined the translocation of p66Shc into mitochondria
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during cardiac IR injury. At the end of the indicated ischemia and/or reperfusion
period, hearts were removed and cytosolic and mitochondrial fractions were
prepared (see Methods), and then subjected to Western blot analyses with anti-
Shc antibody. The level of p66Shc in mitochondria increased by approximately 2-
fold at 10 and 60 min reperfusion, and by approximately 3-fold at 20 min
reperfusion after 30 min ischemia, compared to TC (Fig. 2). The level of p66Shc in
the cytosolic fraction decreased in the 30 min ischemia alone group and in the
30 min ischemia followed by 10, 20 or 60 min reperfusion groups when compared
to the TC and 20 min ischemia groups (Fig. 2).
The incongruity in the reverse changes in p66Shc levels in cytosolic and
mitochondrial fractions in the 30 min ischemia alone group indicated that p66Shc
might translocate to other parts of the cell, including organelles other than
mitochondria. Moreover, the cytosolic p66Shc level was lower in the 30 min
ischemia plus 10 and 20 of reperfusion groups when compared to the 30 min
ischemia plus 60 min of reperfusion group (Fig. 2). These results suggested
greater cell injury/death after 60 min of reperfusion contributed to the lower
p66Shc levels. The translocation of p66Shc into mitochondria during reperfusion
after 30 min ischemia was consistent with phosphorylation of p66Shc at Ser36
during the indicated periods (Fig. 1). Insofar as ischemia alone did not lead to
phosphorylation of p66Shc, correspondingly, ischemia alone (20 or 30 min) also
Figure 1. Phosphorylation of p66Shc at Ser36 increased during reperfusion (R) after ischemia (I) in
isolated guinea pig hearts compared to no ischemia (time controls, TC). A, upper panel: phosphorylation
of p66Shc at Ser36 from total protein lysate of heart tissue. A, lower panel: total p66Shc level for loading control.
Summary of mean band intensities (B) derived from three independent experiments (n53 hearts/group); band
intensities were determined by densitometry using imageJ software and the intensities of P-p66 (Ser36) were
normalized to the total p66Shc in each sample. P,0.05: *IR vs. TC and I.
doi:10.1371/journal.pone.0113534.g001
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did not show significant mitochondrial translocation of p66Shc when compared to
their respective TCs.
Prolonged ischemia required to activate p66Shc during reperfusion
after ischemia
Our previous reports show that the magnitude of ROS production during
ischemia is dependent on the duration of ischemia [15, 20, 27]. Next, we
investigated if the activation of p66Shc was associated with the duration of
ischemia. Guinea pig isolated hearts were subjected to 5, 10, 20 or 30 min
ischemia, followed by 20 min reperfusion. At the end of reperfusion, hearts were
harvested and evaluated for phosphorylation of p66Shc at Ser36. Phosphorylation
of p66Shc at Ser36 increased after 20 min reperfusion following 20 or 30 min
global ischemia, but not after 5 or 10 min ischemia plus 20 min reperfusion
compared to their respective TCs (Fig. 3). These results indicated that at least
20 min ischemia was required for some p66Shc activation during reperfusion after
ischemia.
To evaluate a possible correlation between p66Shc activation and translocation
with the mitochondrial redox state and generation of ROS, online mitochondrial
Figure 2. P66Shc expression levels changed in cytosol and mitochondria during reperfusion after
ischemia. A, upper panel: p66Shc level in mitochondrial and cytosolic fractions. Anti-VDAC (A, middle panel)
and anti-b–actin (A, lower panel) confirm protein loading, mitochondrial (b–actin) and cytosolic purity (VDAC).
Summary of mean band intensities (B) derived from three independent experiments (n53 hearts/group) (see
Fig. 1 for imaging). P,0.05: *IR vs. TC and I20; # IR vs I30; a I30R60 vs I30R10 or I30R20.
doi:10.1371/journal.pone.0113534.g002
Activation and Translocation of p66Shc during Ischemia and Reperfusion
PLOS ONE | DOI:10.1371/journal.pone.0113534 December 1, 2014 8 / 20
NADH and DHE (O2
2N emission) fluorescence intensities were measured during
30 min ischemia and 20 min reperfusion. During early ischemia NADH increased
markedly, but then gradually declined toward baseline levels as ischemia
progressed (Fig. 4A, IR); during reperfusion, NADH was lower than baseline
(Fig. 4A, IR). These findings indicated a shift in mitochondrial redox towards
more oxidized mitochondria during early reperfusion. The corresponding time-
dependent changes in DHE fluorescence signals were characterized by a modest
steady increase during early ischemia and a marked and accelerated increase
during late ischemia (Fig. 4B, IR); the DHE fluorescence signal intensity remained
elevated above baseline during reperfusion in the IR group.
Amobarbital decreased p66Shc activation induced by ischemia and
reperfusion
We next sought to determine if reversible blockade of complex I with amobarbital,
which we showed previously reduced O2
2N emission during IR [15], would reduce
p66Shc activation during reperfusion. To achieve this, hearts were treated with or
without amobarbital (Amo) prior to ischemia followed by 20 or 30 min ischemia
and 20 min reperfusion. At the end of reperfusion, hearts were collected and
evaluated for phosphorylation of p66Shc at Ser36 (see Methods). Compared to the
IR alone group, the amobarbital treated groups exhibited reduced phosphoryla-
tion of p66Shc at Ser36 by 27.5¡0.1% and 14.4¡0.1% at 20 min reperfusion after
20 min (Fig. 5A) and 30 min (Fig. 5B) ischemia, respectively. However,
Figure 3. Phosphorylation of p66Shc at Ser36 during reperfusion after ischemia was dependent on the
duration of ischemia. A, upper panel: phosphorylation of p66Shc at Ser36; A, lower panel: total p66Shc level
for loading control. B: Summary of mean band intensities derived from three independent experiments (n53
hearts/group) (see Fig. 1 for imaging). P,0.05: *I20 and I30 vs. I5, I10 and TC.
doi:10.1371/journal.pone.0113534.g003
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Figure 4. NADH autofluorescence (afu) (A) was higher and DHE fluorescence intensity (O2
2N emission) (B) was lower during ischemia and
reperfusion after amobarbital (Amo) treatment compared to IR alone. DHE and NADH were recorded online in isolated hearts at the LV free wall.
n56 hearts/group/fluorescence measure. Cardiac contractile and relaxant function: developed LVP (C), diastolic LVP (D), dLVP/dtmin (E) and dLVP/dtmax (F)
were improved on reperfusion after amobarbital (Amo) treatment during ischemia. Inset in D shows detailed changes in diastolic LVP during late ischemia
and early reperfusion. n59 hearts/group/functional measure. All values are means¡SEM. TC, time control; IR, ischemia and reperfusion. P,0.05: *IR vs.
TC; #Amo+IR vs. IR.
doi:10.1371/journal.pone.0113534.g004
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phosphorylation of p66Shc at Ser36 in the amobarbital treated groups was
significantly higher than in the TC group. These data indicated, and supported
our previous findings [15], that amobarbital-induced interference with mito-
chondrial electron transfer provides protection, at least in part, by attenuating
p66Shc activation during IR.
Therefore, to ascertain if attenuation of p66Shc activation by amobarbital
correlated with mitochondrial redox state, ROS production, and functional
recovery during IR injury, we monitored NADH, O2
2N generation and several
indices of contractility and relaxation online in amobarbital treated and untreated
hearts during IR. Compared to untreated hearts, amobarbital treated hearts
displayed better preserved mitochondrial NADH levels during 30 min ischemia
and 20 min reperfusion (Fig. 4A; Amo+IR), and a decrease in DHE fluorescence
(O2
2N production) during late ischemia (Fig. 4B; Amo+IR). Moreover, amobar-
bital treatment resulted in a significantly lower diastolic LVP during late ischemia
and early reperfusion (Fig. 4D; Amo+IR) and improved developed LVP, dLVP/
dtmin and dLVP/dtmax during early reperfusion (Fig. 4C, E, F; Amo+IR) compared
to the IR alone group. The incidence of ventricular fibrillation (VF) in the IR
untreated hearts was 100%, with an average of approximately 3 VF occurrences/
heart during reperfusion; amobarbital treated hearts exhibited no incidence of VF
during reperfusion. Each VF that occurred was subsequently reversed to sinus
rhythm with lidocaine. It is noteworthy that although the 20 min ischemia plus
20 min reperfusion group demonstrated activation of p66Shc, there was no
significant compromise in cardiac function or mitochondrial bioenergetics when
Figure 5. IR-induced phosphorylation (P) of p66Shc at Ser36 was decreased by amobarbital (Amo) after
20 (A) or 30 (B) min ischemia (I) followed by 20 min reperfusion (R). A, B, upper panel: phosphorylation of
p66Shc at Ser36; equal amounts of p66Shc loading were verified with anti-ShC antibody (A, B: middle panel).
Summary of mean band intensities derived from three independent experiments (n53 hearts/group) (A, B:
lower panel). IP, immunoprecipitation; TC, time controls (no IR). P,0.05: *IR vs. TC; #Amo+IR vs. IR.
doi:10.1371/journal.pone.0113534.g005
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compared to the TC group (data not shown). This suggested that p66Shc
activation is an early marker of ischemia.
Activation of PKCbII induced by cardiac ischemia and reperfusion
required for p66Shc activation
Next we examined if PKCbII is activated during cardiac IR, and if activation of
p66Shc during reperfusion after ischemia is mediated through PKCbII activated
pathways as previously reported in MEFs [13, 36]. Western blot was used to
determine phosphorylation of PKCbII at Ser660 in hearts subjected to 20 or
30 min ischemia plus 20 min reperfusion. Figure 6A shows that 20 or 30 min
Figure 6. IR-induced activation of p66Shc occurred via the PKCbII signaling pathway. A: Representative WB of 3 independent experiments of
phosphorylation of PKCbII. B: Phosphorylation of p66Shc at Ser36 during IR with or without hispidin (His) treatment. C: p66Shc accumulation in mitochondria
during IR with or without hispidin (His) treatment. B, C Lower panels show summary of mean band intensities derived from three independent experiments
(n53 hearts/group) (see Fig. 1 for imaging). P,0.05: *IR vs. TC; #IR+His vs. IR.
doi:10.1371/journal.pone.0113534.g006
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ischemia plus 20 min reperfusion increased phosphorylation of PKCbII at Ser660,
suggesting IR activated PKCbII. Next we determined if PKCbII activation is
required for p66Shc activation during reperfusion. For this, hearts were treated
with or without hispidin (His) for 10 min before the start of 30 min ischemia plus
20 min reperfusion. At the end of reperfusion, heart tissue was evaluated for
phosphorylation of p66Shc at Ser36; alternatively, mitochondria were isolated
immediately after reperfusion to evaluate mitochondrial p66Shc translocation.
Figures 6B and C show that when hearts were perfused with hispidin before
ischemia compared to IR only (control), both p66Shc phosphorylation at Ser36
and p66Shc mitochondrial translocation were decreased. These observations
support the signaling role of PKCb in activating the oxidoreductase, p66Shc,
during oxidative stress in IR.
We correlated attenuation of p66Shc activation by hispidin with functional
recovery and ventricular infarct size. Figure 7A shows that administration of
hispidin before ischemia significantly reduced diastolic contracture, i.e. diastolic
LVP, when compared to the IR only hearts. The incidence of VF after ischemia
was significantly abated in hearts treated with hispidin before ischemia when
compared to IR only hearts (data not shown). Figure 7B also shows that hispidin
attenuated infarct size to 33¡3% compared to the untreated IR (control) group
in which infarct size was 45¡3%. These results showed that ischemia followed by
reperfusion induces p66Shc activation through the PKCbII signaling pathway to
contribute to IR injury.
Discussion
We have demonstrated that p66Shc is activated and translocated into
mitochondria during global no-flow IR in the ex vivo perfused heart model.
Activation of p66Shc and its subsequent translocation into mitochondria are
dependent both on the duration of ischemia and on the occurrence and timing of
reperfusion after ischemia. Reversible attenuation of respiration via complex I by
amobarbital reduced both ROS emission and activation of p66Shc and improved
function on reperfusion. Inhibiting PKCb during IR with hispidin reduced
activation/translocation of p66Shc, improved cardiac function, and decreased cell
injury. Thus, p66Shc is both a marker and a mitochondrial effector of oxidative
stress-mediated mitochondrial dysfunction and ROS production. The effects of
amobarbital on reducing mROS emission, improving redox state, and attenuating
p66Shc activation during IR injury, suggest an important link between oxidative
stress and activation of p66Shc.
P66Shc is activated during reperfusion after global cardiac
ischemia
IR injury can occur under a number of situations including cardiac arrest and
resuscitation, hypoxia and reoxygenation, and coronary artery occlusion and
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reperfusion. Although ischemia itself can induce cardiac injury, much of the
injury occurs during early reperfusion [37]. The causative and interactive factors
of myocardial reperfusion injury include excess ROS, Ca2+ overload, and
induction of apoptosis [38]. It is well known that the major source of ROS
emission during reperfusion in cardiomyocytes is the ETC, which is progressively
damaged during ischemia and contributes to further ROS generation during
reperfusion [2, 20, 39–41].
However recent studies showed that p66Shc may also act as an oxidoreductase to
generate H2O2 in mitochondria after activation following redox stimulation [6].
Furthermore, in the mouse isolated heart model of IR injury, p66Shc2/2 mice
showed less susceptibility to IR injury than wild type mice [11]. In the present
study, we showed that p66Shc only becomes activated and translocated to
mitochondria during reperfusion after 20 or 30 min ischemia (Figs. 1, 2 and 3).
Figure 7. Inhibiting PKCb activation reduced cardiac damage after IR. A: Diastolic LVP without IR (TC;
n58 hearts/group) and before ischemia, at 30 min of ischemia and at 20 min of reperfusion (IR; n512 hearts/
group) with or without hispidin (His; n510 hearts/group) treatment. B: Infarct size after 30 min of ischemia and
120 min of reperfusion (n58 hearts/group) with or without hispidin (His; n58 hearts/group) treatment.
P,0.05: #IR+His vs. IR.
doi:10.1371/journal.pone.0113534.g007
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This suggests that p66Shc could also contribute to mROS generation during IR
injury especially during reperfusion after ischemia. Why p66Shc is activated only
during reperfusion is unclear, but it is possible that the preceding events during
ischemia (e.g. excess ROS emission) followed by restoration of flow, O2 and
substrate supply, and by the rapid re-establishment of a reduced redox state and
OxPhos, may collectively contribute to p66Shc activation.
Ischemia, when prolonged, irreversibly disrupts electron transfer during
reperfusion, yet ETC complexes I–III may not be the only sources of ROS during
reperfusion [41]. It is possible that during the reperfusion phase of IR injury,
p66Shc induces additional ROS generation via a putative direct effect on
oxidoreductase activity, which depends on electron leak from upstream complexes
(e.g. I and III) and then becomes an additional source of ROS production [6, 13]
that may exacerbate the ROS generated from damaged complexes. This could
initiate a vicious cycle of excess ROS emission by mitochondrial ROS-induced-
ROS release (RIRR) during reperfusion.
Long duration of ischemia with reperfusion is necessary for p66Shc
activation
We found that 5 and 10 min ischemia plus 20 min reperfusion did not increase
activation of p66Shc, whereas 20 and 30 min ischemia with reperfusion increased
p66Shc activation markedly. This indicated that a longer duration of ischemia plus
reperfusion was required to activate p66Shc. The duration of ischemia is generally
linked to the extent of injury to ETC complexes [41, 42]. In rats, complex I activity
decreased early in ischemia, whereas complex III damage occurred only after a
longer ischemia time [41, 43]. Consistent with the time-dependent ischemic
damage to ETC complexes, ROS emission also displays an ischemia duration
dependent pattern. In the guinea pig heart, we showed a correlation between
NADH, O2
2N levels and duration of ischemia (Fig. 4A, B) [15, 18, 24]. Our present
(Fig. 4B) and past [15, 27] results in guinea pig isolated hearts showed small
amounts of O2
2N were generated during early (1–20 min) global ischemia
followed by a marked surge in O2
2N generation during late (25–30 min) global
ischemia. Therefore, the longer durations of ischemia (20 and 30 min), when
followed by at least 10 min reperfusion, are likely to have induced ETC complex
damage leading to enhance ROS emission. Excess ROS (possibly H2O2), beyond a
certain threshold, may act as deleterious redox-signaling molecules that lead to
activation of p66Shc, which in turn enhances mROS generation to induce further
oxidative damage to ETC complexes leading to RIRR.
Unlike 30 min ischemia, 20 min ischemia (both followed by 20 min
reperfusion) induced p66Shc activation (Fig. 3), but had no significant effect on
cardiac function on reperfusion (data not shown). This suggests that p66Shc is
more sensitive to redox modulation than the measured cardiac function during IR
injury. These observations show overall that p66Shc participates in emitting ROS
involved in cardiac dysfunction during longer ischemia times as with reperfusion.
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Amobarbital decreases activation of p66Shc during cardiac IR
injury
Our current and previous studies [15] show that amobarbital, when present
during ischemia and early reperfusion, preserved NADH (Fig. 4A), minimized
O2
2N emission (Fig. 4B), and reduced mitochondrial Ca2+ overload [15], which
concomitantly improved functional recovery (Fig. 4 C–F) and reduced infarction
when compared to IR only (control) [15]. Furthermore, in this study we also
found that compared to IR alone, amobarbital reduced activation of p66Shc
induced by ischemia and reperfusion (Fig. 5). Since amobarbital reversibly binds
at the rotenone site of complex I to attenuate electron transfer [17, 44, 45], this
suggests that amobarbital, when present in the tissue during ischemia, attenuates
activation of p66Shc by blunting electron transfer to reduce O2
2N generation. Our
observations further suggest that amobarbital better protected mitochondria and
reduced myocardial injury during reperfusion, possibly due to attenuated p66Shc
activation and its concomitant translocation into mitochondria to modulate ROS
emission.
When p66Shc is activated and translocated into mitochondria, it becomes a pro-
apoptotic protein that induces apoptosis by altering the redox state [6]; however,
the detailed mechanism for this remains unclear [46]. Amobarbital-induced
attenuation of p66Shc activation during IR demonstrates that p66Shc is affected by
electron transfer related events that modulate the ETC. Thus, insofar as
amobarbital was presumed present in the myocardium during ischemia, it may
have reduced activation of p66Shc during reperfusion by decreasing ischemic ROS
emission. Hence, the amobarbital-induced decrease in ROS production during
ischemia appears to decrease ROS emission on reperfusion, attenuate activation of
cytosolic PKCbII, reduce activation and translocation of p66Shc into mitochon-
dria, and ultimately, decrease mitochondrial and cellular damage.
PKCb induces p66Shc activation and its translocation into
mitochondria during IR
The signaling pathways that lead to p66Shc phosphorylation at Ser36 during
cardiac ischemia and/or reperfusion have not been reported before. In this study,
we show that inhibiting PKCb with hispidin reduced both p66Shc phosphorylation
at Ser36 and mitochondrial translocation during IR (Fig. 6 B and C). These results
indicate that p66Shc activation and its eventual translocation into mitochondria
during IR likely occur through PKCb-mediated signaling pathways; this is
consistent with previous studies in which different stress models were used
[13, 36, 47]. Several previous reports show common p66Shc phosphorylation
signaling pathways, indicating an independence of the stimulus and cell type. For
example, incubation of human endothelial cell with oxidized LDL led to
phosphorylation [36] of p66Shc; in MEFs, treatment with H2O2 and UV induced
phosphorylation [13] of p66Shc; and A549 and RAW 264.7 cells treated with
Taxol, an antitumor drug, induced phosphorylation [48] of p66Shc. Among these
stimuli and cell types, the signaling pathways that induce p66Shc phosphorylation
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first involve activating PKCb [13, 36], followed by activation of other kinases
[36, 47, 48] that directly induce phosphorylation of p66Shc at Ser36 [36].
The role of PKCbII in modulating cardiac function also has been reported.
Kong et al. [14] observed significant increases in PKCbII cell membrane
translocation and phosphorylation after 30 min of LAD occlusion followed by
30 min reperfusion. Moreover, PKCb2/2, or its blockade with ruboxistaurin,
reduced infarct size by 2.6 fold after 30 min regional ischemia and 48 h
reperfusion in mice. Consistent with these findings, we found PKCbII was
activated (specifically by its phosphorylation at Ser660) during IR (Fig. 6A).
Furthermore, hispidin, when given before ischemia, reduced diastolic contracture
(Fig. 7A) and infarct size (Fig. 7B). Although other studies also show that
inhibition of PKCb activation is protective against cardiac IR injury, our study
provides evidence that PKCbII modulates cardiac IR injury by triggering the
activation and translocation of p66Shc into mitochondria (Fig. 6B, C).
Summary, Conclusions and Limitations
We provide evidence that p66Shc is activated and translocated from the cytosol
into mitochondria in cardiac IR injury. Activation of p66Shc occurred only during
reperfusion via PKCbII activation. The magnitude of p66Shc activation correlated
with the degree of cell damage, so that the greatest activation/translocation of
p66Shc had the worst functional recovery, a higher incidence of VF, and a greater
infarct size. Reversible blockade of complex I reduced the ROS level necessary to
activate p66Shc. These observations imply that excess ROS and altered redox state
resulting from IR injury are single or combined factors that initiate p66Shc
activation and mitochondrial translocation.
Persistent activation of p66Shc may lead to a vicious cycle of mitochondrial
RIRR as a result of redox-sensitive activation of PKCbII. Therefore, preventing
p66Shc activation may reduce the feed-forward cycle of RIRR and lessen
reperfusion injury. The findings that p66Shc mediates only detrimental ROS
production during reperfusion provides a novel opportunity for pharmacological
interventions that would target this redox-signaling cascade leading to p66Shc
activation and translocation into mitochondria after the onset of cardiac IR
injury. Overall, this study provides additional valuable insights into the possible
mechanisms of how modulating electron transfer along the ETC can minimize
deleterious ROS emission during cardiac IR injury as a means to improve cardiac
function. A potential limitation is that attenuation of p66Shc translocation into
mitochondria by modulating electron transfer is less pronounced than the effect
on functional recovery, which indicates that other factors in addition to the effects
of p66Shc on translocation exert a role on ROS emission during the progression of
ischemia into reperfusion.
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